Thymalfasin (thymosin alpha-1) demonstrated durable sustained response rates in chronic hepatitis B with excellent tolerability, supporting its use as an immune-based HBV therapy alternative to interferon.
Key findingThymalfasin achieved sustained HBV virological response with increasing durability over follow-up and minimal side effects, positioning it as a well-t
What the researchers found
Thymalfasin achieved sustained HBV virological response with increasing durability over follow-up and minimal side effects, positioning it as a well-tolerated immune-based alternative for chronic hepatitis B treatment.
Why it matters
Relevant for thymosin-alpha-1, infection, immune-function, clinical-trials.
How the study worked
review study on thymosin-alpha-1, infection.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2004.
The bigger picture
Advances peptide therapeutics research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
Journal of gastroenterology and hepatology, 19(12), S73-5
Citation
Liaw, Yun-Fan. (2004). Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.. Journal of gastroenterology and hepatology, 19(12), S73-5.